Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Panda blood kills bacteria in one hour
Antibacterial compound found in giant pandas

New research has found that giant panda blood contains a compound that kills bacteria in less than one hour, which is six times quicker than well-known antibiotics.

Scientists at the Life Sciences College of Nanjing Agricultural University in China were analysing panda DNA when they came across the blood's primary component, cathelicidin-AM.

The scientists suspect the powerful component is present in order to boost giant pandas' immune systems and protect them from infections when living in the wild.

Xiuwen Yan, who led the research, explained that giant panda blood "showed potential antimicrobial activities against wide spectrum of microorganisms including bacteria and fungi, both standard and drug-resistant strains".

The team has been able decode panda genes to form a molecule called a peptide, allowing them to produce cathelicidin-AM in the laboratory. This means the compound can be supplied without the need to extract blood from giant pandas.

Yan continued: "Under the pressure of increasing microorganisms with drug resistance against conventional antibiotics, there is urgent need to develop new type of antimicrobial agents.

"Gene-encoded antimicrobial peptides play an important role in innate immunity against noxious microorganisms. They cause much less drug resistance of microbes than conventional antibiotics."

The new discovery is said to reflect the importance of all species, particularly as they may hold they key to solving pressing health issues in both animals and humans. It is reported that there are only 1,600 pandas left living in the wild.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.